A comparative study of aripiprazole treatment for co-morbid attention deficiency hyperactivity disorder in ;children with Tourette syndrome
10.3969/j.issn.1002-0152.2016.03.006
- VernacularTitle:阿立哌唑治疗Tourette综合征共患注意缺陷多动障碍研究
- Author:
Hejian YANG
;
Fuye ZHANG
;
Baohai SHI
;
Yameng LIU
;
Xinli YANG
;
Liping CHEN
;
Sumei ZHANG
- Publication Type:Journal Article
- Keywords:
Tourette syndrome;
Attention deficiency hyperactivity disorder;
Haloperidol;
Children
- From:
Chinese Journal of Nervous and Mental Diseases
2016;42(3):156-160
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of aripiprazole treatment for co-morbid attention defi?ciency hyperactivity disorder (ADHD) in children with Tourette syndrome (TS). Methods Forty four TS children with co-morbid ADHD were randomly divided into aripiprazole group and haloperidol group. The aripiprazole group and halo?peridol group received aripiprazole and haloperidol treatment for 12 weeks, respectively. Yale global tic severity scale (YGTSS) and Conners parent symptom questionnaire (PSQ) were used to assess the tic and ADHD symptoms before, 2, 4, 8 and 12 weeks after treatment. Side effects were recorded weekly. Results Repeated measure ANOVA indicated that the main effects of groups was not significant to the YGTSS scores (P>0.05), but significant to the PSQ scores (P<0.05). After 12-week treatment, the YGTSS scores between two groups were not significantly different (P>0.05). The PSQ scores of aripiprazole group were significantly lower than that of haloperidol group. The adverse reactions of aripiprazole group were milder compared with the haloperidol group (P<0.05). Conclusions The present study demonstrates that aripipra?zole has the same efficacy in the treatment of tics as haloperidol, improves co-morbid ADHD symptoms, and its adverse reactions are much less compared with haloperidol.
